Cooper Companies (NASDAQ:COO) Updates FY 2026 Earnings Guidance

Cooper Companies (NASDAQ:COO) issued an update on its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 4.510-4.550 for the period, compared to the consensus EPS estimate of 4.630. The company issued revenue guidance of $4.2 billion-$4.3 billion, compared to the consensus revenue estimate of $4.3 billion. Cooper Companies also updated its Q4 2026 guidance to 1.050-1.090 EPS.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on COO shares. Bank of America restated a “neutral” rating and issued a $65.00 price objective (down from $80.00) on shares of Cooper Companies in a research report on Thursday. The Goldman Sachs Group set a $61.00 target price on shares of Cooper Companies in a research report on Wednesday, May 27th. JPMorgan Chase & Co. cut their price objective on Cooper Companies from $71.00 to $58.00 and set a “neutral” rating for the company in a report on Thursday. Needham & Company LLC decreased their price target on shares of Cooper Companies from $86.00 to $73.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, William Blair cut shares of Cooper Companies from an “outperform” rating to a “market perform” rating in a research report on Thursday. Five analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $71.47.

Cooper Companies Stock Down 14.7%

Shares of NASDAQ COO opened at $54.17 on Friday. The firm has a fifty day simple moving average of $72.02 and a two-hundred day simple moving average of $69.81. The firm has a market capitalization of $10.56 billion, a PE ratio of 18.49, a price-to-earnings-growth ratio of 1.66 and a beta of 0.82. The company has a current ratio of 1.27, a quick ratio of 0.78 and a debt-to-equity ratio of 0.23. Cooper Companies has a 12 month low of $51.01 and a 12 month high of $89.83.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.12 by $0.03. Cooper Companies had a net margin of 13.46% and a return on equity of 10.92%. The business had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same period last year, the business posted $0.49 earnings per share. Cooper Companies’s quarterly revenue was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Equities analysts expect that Cooper Companies will post 4.63 earnings per share for the current year.

Cooper Companies declared that its Board of Directors has initiated a share repurchase plan on Wednesday, September 9th that allows the company to buyback $3.00 billion in shares. This buyback authorization allows the medical device company to repurchase up to 22.7% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Trending Headlines about Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper Companies reported fiscal third-quarter adjusted EPS of $1.15, above the roughly $1.11–$1.12 analyst consensus. Free cash flow increased 66% to $273 million, and the company repurchased $339.1 million of stock. CooperCompanies Announces Third Quarter 2026 Results
• Positive Sentiment: The board expanded its share-repurchase authorization from $2 billion to $3 billion, potentially allowing the company to buy back as much as 22.7% of outstanding shares. The authorization signals management’s belief that the stock is undervalued and could support per-share results. CooperCompanies Completes Strategic Review
• Neutral Sentiment: Reported short-interest data showed zero shares short and a zero-day days-to-cover ratio, indicating no meaningful short-interest signal; the figures may reflect incomplete or anomalous data.
• Negative Sentiment: Third-quarter revenue of approximately $1.07 billion missed the $1.10 billion consensus estimate. Management cited U.S. channel inventory reductions and destocking pressure affecting CooperVision and reduced its fiscal 2026 adjusted EPS outlook to $4.51–$4.55, below the $4.63 consensus. Fourth-quarter EPS guidance of $1.05–$1.09 also fell short of expectations. Why Cooper Stock Plunges After Earnings
• Negative Sentiment: Cooper completed its strategic review but decided not to sell or pursue a transaction for CooperSurgical. Investors appear disappointed because a sale could have unlocked value, while fertility-related litigation and competitive pressure from a new non-hormonal IUD add uncertainty. Cooper Cos. Stock Drops After Soft Outlook
• Negative Sentiment: Analysts lowered targets and ratings following the results: JPMorgan cut its target to $58 and UBS to $66, both with neutral ratings; William Blair downgraded the stock to market perform; and Robert W. Baird moved from strong buy to hold with a $61 target.
• Negative Sentiment: Law firms announced securities-fraud investigations concerning whether Cooper Companies adequately disclosed business conditions and the factors behind the outlook reduction, creating an additional overhang for investors. Securities Fraud Investigation Announcement

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Cresset Asset Management LLC raised its stake in shares of Cooper Companies by 7.5% during the 3rd quarter. Cresset Asset Management LLC now owns 4,393 shares of the medical device company’s stock worth $301,000 after buying an additional 306 shares during the last quarter. Captrust Financial Advisors grew its position in shares of Cooper Companies by 10.0% in the second quarter. Captrust Financial Advisors now owns 3,500 shares of the medical device company’s stock valued at $249,000 after purchasing an additional 317 shares during the last quarter. Snowden Capital Advisors LLC increased its stake in shares of Cooper Companies by 10.0% during the 2nd quarter. Snowden Capital Advisors LLC now owns 4,088 shares of the medical device company’s stock worth $291,000 after purchasing an additional 373 shares in the last quarter. Public Employees Retirement System of Ohio raised its position in shares of Cooper Companies by 0.6% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 62,229 shares of the medical device company’s stock worth $4,266,000 after purchasing an additional 386 shares during the last quarter. Finally, Arkadios Wealth Advisors lifted its stake in Cooper Companies by 14.3% in the 4th quarter. Arkadios Wealth Advisors now owns 3,552 shares of the medical device company’s stock valued at $291,000 after buying an additional 444 shares in the last quarter. Institutional investors own 24.39% of the company’s stock.

Cooper Companies Company Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.